证券简称：盘龙药业 证券代码：002864 陕西盘龙药业集团股份有限公司 向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐机构（主承销商） 济南市市中区经七路 86 号 二零二三年六月 1-1-1 陕西盘龙药业集团股份有限公司向特定对象发行 A 股股票 募集说明书 3、研发失败导致发行人盈利能力下降的风险 重大事项提示 公司特别提示投资者对下列重大风险给予充分关注，并仔细阅读本募集说明书中有 关风险因素的章节。 （一）高壁垒透皮给药系统研发平台建设项目研发风险 1、研发失败风险 医药产业链具有高度细分的特点，为提升透皮给药项目的研发效率和成功率，公司 顺应行业发展趋势，拟采用与 CRO 机构合作的形式进行。公司将委托 CRO 机构进行 阶段性、专业性的研究，并搭建自有团队，配备临床专员和观察员，掌握和管理研发进 度。公司已与博腾股份的全资子公司博腾药业签署协议，合作开发 PLJT-001 和 PLJT-002； 已与博济医药合作开发 PLJT-003，并已与博济医药全资子公司杏林中医药合作开发 PLJT-004。考虑到药品研发的风险性特征，包括技术工艺复杂，研发周期较长等特点， 尤其是，PLJT-00 ...

关于同意陕西盘龙药业集团股份有限公司 向特定对象发行股票注册的批复 陕西盘龙药业集团股份有限公司: 中国证券监督管理委员会收到深圳证券交易所报送的关于你 公司向特定对象发行股票的审核意见及你公司注册申请文件。根 据《中华人民共和国证券法》《中华人民共和国公司法》《国务院 办公厅关于贯彻实施修订后的证券法有关工作的通知》(国办发 〔2020〕5 号）和《上市公司证券发行注册管理办法》(证监会令 第 206号)等有关规定,经审阅深圳证券交易所审核意见及你公 司注册申请文件,现批复如下: 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送深圳证券交易所的申报 文件和发行方案实施。 三、本批复自同意注册之日起 12个月内有效。 中国证券监督管理委员会 证监许可〔2023〕1709 号 四、自同意注册之日起至本次发行结束前,你公司如发生重 2023 8 2 ...

证券代码： 002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|--------------------| | | | 编号：2023-05-16 | | 投资者关系活动 | □ 分析师会议 | | | 类别 | 业绩说明会 | | | | 路演活动 | | | | | | | | （请文字说明其他活动内容） | | | 参与单位名称及 | | | | 人员姓名 | | | | 时间 | 周二) 下午 15:00~17:00 | | | 地点 | | https://ir.p5w.net | | | | | | 上市公司接待人 | | | 员姓名医药研究院院长张德柱 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、医药行业市场竞争加剧，请问公司如何应对？ 尊敬的投资者您好！面对激烈的竞争格局，应该增加创新性 产品推出，加强中医药科学研究,中医药经典名方的研制，加强 中药资源保护利用，推进中药材规范化种植养殖， ...

关于参加"2023 年陕西辖区上市公司投资者集体接待日 暨 2022 年度业绩说明会"的公告 证券代码：002864 证券简称：盘龙药业 公告编号：2023-067 陕西盘龙药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者的沟通交流，进一步提升投资者关系管理水平，陕西上市公司协会根据 陕西证监局工作部署，联合深圳市全景网络有限公司举办"2023 年陕西辖区上市 公司投资者集体接待日暨 2022 年度业绩说明会活动"。 届时，公司董事长及相关高管人员将通过互动平台与投资者进行网络沟通和 交流，欢迎广大投资者踊跃参加！ 活动时间：2023 年 5 月 16 日（星期二） 15:00-17:00。 陕西盘龙药业集团股份有限公司董事会 2023 年 5 月 11 日 活动地址："全景路演"。 网址：http://rs.p5w.net 。 特此公告。 ...

证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2023-05-05 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 天风证券、国联证券、华安医药、申万元宏源证券、红土创新基金、西 藏源乘投资、长城证券、南方基金、招商基金、上投摩根基金、华宝基金、 博时基金、东方基金、前海开源、恒大人寿、长盛基金、东吴基金、浦银安 盛基金、东北证券、合众资产、中加基金、永安国富、云溪基金、中新融创、 参与单位名称 厦门金恒宇、东兴基金、云溪基金、江苏瑞华投资、泰康香港、上海途灵资 产、华夏久盈资产、上海域秀资产、中信保诚基金、西部利得基金、循远资 及人员姓名 产、上海方物私募、金信基金、西部利得基金、上海睿亿投资、信诚基金、 兴银理财、上海益理资产、上海运舟私募、金信基金、博道基金、上海楹联 投资、青骊投资管理、交银国际信托、国寿资产、上海原泽私募、浙江韶夏 投资、交通银行、Dymon Asia Capital (HK) 、LyGH 等 时间 2023 年 04 月 28 ...

Group 1: Financial Performance - The company's total assets increased by 45.15% in 2022, with cash increasing by 96.38% and accounts receivable rising by 22.75% [3] - Revenue growth for 2022 was 9.78%, while net profit grew by 8.58%, indicating a stable financial performance [3] - The main product, Panlong Qipian, sold approximately 12 million boxes in 2022, generating sales revenue of 428.42 million yuan [2] Group 2: Research and Development - The company has gradually increased R&D investment, with expenditures of 12.97 million yuan, 14.03 million yuan, and 18.23 million yuan over the past three years [12] - The company has established partnerships with several universities and research institutions to enhance its R&D capabilities [6] - The R&D pipeline includes various new drug projects, with a focus on traditional Chinese medicine and modern formulations [9] Group 3: Market Strategy - The company aims for double-digit revenue growth in 2023, with a focus on expanding its marketing network and enhancing production quality [5] - The "One Body, Two Wings" strategy is designed to strengthen the pharmaceutical manufacturing and commercial distribution sectors [10] - The company plans to increase its market share in key regions such as North China, East China, and South China while also targeting grassroots markets [4] Group 4: Product Development - The company has developed a diverse range of health products, including oral care, health supplements, and functional foods [9] - Panlong Qipian is recognized as a unique medical insurance category A product, with ongoing research to enhance its evidence-based medical credentials [4] - The company has established a comprehensive supply chain for raw materials, with over 18,000 acres dedicated to medicinal herb cultivation [4] Group 5: Internal Control and Risk Management - The company has implemented a robust internal control system to monitor and manage operational risks effectively [11] - An internal audit department has been established to ensure compliance with regulations and improve operational efficiency [11] - The company emphasizes the importance of risk management in its long-term development strategy [11]

证券代码： 002864 证券简称：盘龙药业 编号：2023-05-08 | 投资者关系活动 | □特定对象调研 分析师会议 □ | | --- | --- | | 类别 □ | 业绩说明会 媒体采访 √ | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 8 日 (周一) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人 | 董事长兼总经理谢晓林、副总经理兼董事会秘书吴杰、财务总监祝凤鸣、 | | 员姓名 | 独立董事任海云、独立董事焦磊鹏、中泰证券投资银行业务委员会副总裁 | | | 杨圣志 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问盘龙 ESG 方面是如何规划的？ | | | 尊敬的投资者您好！公司非常重视 ...

Financial Performance - Shaanxi Panlong Pharmaceutical Group reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-on-year increase of 15%[31]. - The company achieved a net profit of RMB 300 million in 2022, which is a 20% increase compared to the previous year[31]. - The company's operating revenue for 2022 was ¥974,293,135.49, representing a 9.78% increase from ¥887,484,877.11 in 2021[37]. - The net profit attributable to shareholders for 2022 was ¥101,163,536.29, an increase of 8.58% compared to ¥93,169,906.99 in 2021[37]. - The gross margin for 2022 was reported at 45%, reflecting improved operational efficiency[31]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-on-year growth of 20%[165]. - The company achieved an annual revenue of ¥974,293,135.49, representing a year-on-year growth of 9.78%[95]. - The company plans to enhance its core competitiveness in traditional Chinese medicine while exploring product upgrades and innovation, focusing on "specialized, refined, unique, and new" strategies[150]. Product Development and Innovation - The company is expanding its product line and has successfully passed certification for health food and product workshops, enhancing its operational capacity[10]. - The company plans to launch three new products in 2023, focusing on traditional Chinese medicine, which is expected to contribute an additional RMB 200 million in revenue[31]. - The company is actively pursuing opportunities for market expansion and potential mergers and acquisitions to strengthen its competitive position[63]. - The company is developing several new products, including PLC-01 for coronavirus treatment and PLJT-001 for orthopedic pain management[120]. - The company has developed 23 health products and 2 medical devices, all of which have completed registration and are ready for market[98]. - The company plans to accelerate the research and development of innovative drugs, including the secondary development of major products and external medications, with a focus on traditional Chinese medicine granules and classic formulas[150]. - The company aims to enhance its innovation capabilities and strengthen the supply chain for high-end biopharmaceutical products as outlined in the national development plans[55]. Market Expansion and Strategy - The company aims to increase its market share by 10% in the next fiscal year through strategic partnerships and marketing initiatives[31]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[165]. - The company is set to launch three new products in Q3 2023, anticipated to contribute an additional 200 million RMB in revenue[165]. - The company aims to develop untapped county-level markets to drive sales growth through a dual-channel strategy of clinical and retail sales[161]. - The company is actively exploring industrial upgrade paths and second growth curves through the integration of industry and finance[104]. Research and Development - The company is investing RMB 50 million in R&D for new technologies related to drug formulation and production processes[31]. - The company plans to invest approximately 3% of its annual revenue into R&D to enhance its innovative capabilities[69]. - The company established the Panlong Pharmaceutical Research Institute in November 2018 to foster a collaborative "industry-university-research" platform[69]. - The company has implemented advanced production techniques, such as GMP standards, to ensure product quality across its health supplement range[67]. - The company has focused on expanding its market presence in orthopedics and rehabilitation, leveraging relationships with professional associations to drive brand growth[102]. Social Responsibility and Governance - The company is committed to social responsibility, investing in healthcare, education, and poverty alleviation through a charitable fund[12]. - The company emphasizes social responsibility while maximizing shareholder value, actively engaging with stakeholders to promote sustainable development[176]. - The company is committed to environmental protection and aims to create an ecological factory while exploring industrial tourism to enhance brand awareness[156]. - The company has a strong commitment to党建 (Party Building) to drive high-quality development, with 71 formal party members and a focus on integrating党建 into corporate governance[94]. Financial Management and Compliance - The company adheres to strict information disclosure regulations, ensuring transparency and protecting shareholder rights, particularly for minority shareholders[174]. - The company has established a dedicated investor relations management system, facilitating communication through various channels to ensure equal access to information for all shareholders[175]. - The company maintains an independent governance structure, ensuring that its operations are distinct from those of its controlling shareholders[180]. - The company has established a comprehensive financial accounting system, allowing for independent financial decision-making and tax compliance[184]. Market Trends and Opportunities - The company has identified significant growth opportunities in the traditional Chinese medicine sector, supported by government policies[49]. - The establishment of geriatric medicine departments in secondary and higher-level hospitals is expected to reach 60% by 2025, which will benefit the market for musculoskeletal system medications[52]. - The company is positioned to benefit from the increasing health awareness and the shift in healthcare spending from treatment to preventive care, particularly in the context of an aging population[56]. - The company faces risks from industry policy changes and plans to adapt its strategies to align with national healthcare reforms and regulations[159].

Financial Performance - The company's revenue for Q1 2023 was CNY 225,625,209.86, representing a 13.48% increase compared to CNY 198,828,511.27 in the same period last year[4] - Net profit attributable to shareholders was CNY 21,561,607.43, up 7.37% from CNY 20,081,539.34 year-on-year[4] - Total operating revenue for Q1 2023 reached CNY 225,625,209.86, an increase of 13.5% compared to CNY 198,828,511.27 in Q1 2022[24] - Net profit for Q1 2023 was CNY 21,812,305.64, representing an increase of 7.4% from CNY 20,311,464.87 in Q1 2022[25] - The total comprehensive income for the period was CNY 21,812,305.64, compared to CNY 20,311,464.87 in the previous period, reflecting an increase of approximately 7.4%[26] - The company reported a basic earnings per share of CNY 0.24, up from CNY 0.23 in the previous period, representing an increase of about 4.3%[26] Cash Flow - The net cash flow from operating activities significantly decreased by 96.14%, amounting to CNY 1,522,659.83 compared to CNY 39,416,073.24 in the previous year[4] - The net cash flow from financing activities decreased by 102.93% to CNY -10,705,969.23, primarily due to the previous period's fundraising from convertible bonds[9] - The total cash inflow from financing activities was CNY 100,213,637.50, down from CNY 414,450,344.29 in the previous period, indicating a decrease of approximately 75.8%[29] - The net cash flow from financing activities showed a net outflow of CNY 10,705,969.23, contrasting with a net inflow of CNY 365,916,650.78 in the previous period[29] - The cash and cash equivalents at the end of Q1 2023 amounted to RMB 796.26 million, down from RMB 823.44 million at the beginning of the year[21] - The cash and cash equivalents at the end of the period were CNY 796,263,057.99, a decrease from CNY 805,044,185.42 in the previous period[29] Assets and Liabilities - The company's total assets decreased by 0.86% to CNY 1,914,264,568.03 from CNY 1,930,786,964.46 at the end of the previous year[4] - The total liabilities decreased to CNY 711,604,108.49 from CNY 983,183,297.68, indicating a reduction of 27.6%[23] - The equity attributable to shareholders increased by 27.41% to CNY 1,184,456,817.61 from CNY 929,650,723.07 at the end of the previous year[4] - The equity attributable to shareholders increased to CNY 1,184,456,817.61 from CNY 929,650,723.07, reflecting a growth of 27.4%[23] Operating Costs and Expenses - The company reported a 33.41% increase in operating costs, totaling CNY 114,243,787.63, primarily due to increased sales volume and changes in product sales structure[8] - Total operating costs amounted to CNY 200,170,026.24, up from CNY 172,988,132.13, reflecting a year-over-year increase of 15.7%[25] - Research and development expenses rose by 60.70% to CNY 3,280,480.41, reflecting increased investment in R&D[8] - Research and development expenses for the quarter were CNY 3,280,480.41, up from CNY 2,041,330.57, marking a significant increase of 60.9%[25] - The company paid CNY 21,712,469.37 to employees, which increased from CNY 19,478,731.73 in the previous period, reflecting an increase of about 11.3%[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,594[10] - The largest shareholder, Xie Xiaolin, holds 38.37% of the shares, amounting to 37,189,932 shares[10] Convertible Bonds - The company issued 2,760,000 convertible bonds with a total issuance amount of RMB 276 million, netting RMB 271.98 million after expenses[13] - As of March 29, 2023, there were 49,743 unconverted "Panlong Convertible Bonds" redeemed at a price of RMB 100.05 per bond, totaling RMB 4.98 million[14] - The company plans to issue A-shares to specific investors, with the proposal approved by the shareholders' meeting[16] Credit and Inventory - The company experienced a 441.62% increase in credit impairment losses, amounting to CNY -1,815,375.48, attributed to an increase in accounts receivable[9] - The company's accounts receivable rose to CNY 460,578,034.96, compared to CNY 443,556,640.27 in the previous quarter, showing an increase of 3.2%[23] - Inventory levels increased to CNY 96,221,666.87 from CNY 94,628,102.72, reflecting a growth of 1.7%[23]

证券代码：002864 证券简称：盘龙药业 公告编号：2023-065 陕西盘龙药业集团股份有限公司 关于举行 2022 年年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司董事会 2023 年 4 月 28 日 陕西盘龙药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《2022 年年度报告》。 为便于广大投资者深入了解公司情况，公司定于 2023 年 5 月 8 日（星期一） 15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩说明会将采用网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 录 全 景 网 " 投 资 者 关 系 互 动 平 台 " （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理谢晓林先生，董事、 副总经理兼董事会秘书吴杰先生，财务总监祝凤鸣先生，独立董事任海云女士， 独立董事焦磊鹏先生，中泰 ...